FUSIX Technology

Oncolytic Virotherapy

As multi-mechanistic antitumor agents, oncolytic viruses are emerging to be potent immunotherapeutic treatment options in different tumor indications. Oncoytic viruses specifically replicate in tumor cells due to altered signalling pathways supporting the tumor’s immune esape, leaving open replication advantages for viruses susceptible to intact signaling pathways.​

FUSIX Technology

The FUSIX Technology relies on a fusion-based oncolytic virus platform. Below you can see FUB101 in action.

In this timelapse video FUB101 is killing a monolayer of cancer cells (HCC) within 48 hours through a fusogenic mechanism of action.

The FUSIX technology is based on a hybrid virus construct combining all the advantages of both parental platforms while minimizing risks factors. This results in an oncolytic virus platform with an excellent safety profile and effective replication kinetics. Tumor-selective replication leads to significant oncolytic activity, while fusion-based cell death adds to its potent immune-stimulatory properties.

Together this results in tumor regression and systemic tumor-specific immunity

Combination Immunotherapy Using the FUSIX Platform

Oncolytic viruses have been identified as highly promising candidates for combination immunotherapies, because of their potential to induce immune cell infiltration and breakdown of the tumor immune tolerance. Additionally, they activate a response against neoepitopes that are released by an immunogenic cell death of infected tumor cells. The FUSIX technology offers a potent and flexible platform for combination approaches with immune checkpoint inhibitors, as well as adoptive cell transfer, including T cells as well as dendritic cells.


Abdullahi et al. (2018)
A Novel Chimeric Oncolytic Virus Vector for Improved Safety and Efficacy as a Platform for the Treatment of Hepatocellular Carcinoma.
Journal of Virology

Krabbe T., Altomonte J. (2018) Fusogenic Viruses in Oncolytic Immunotherapy.

Krabbe et al. (2021)
Adoptive T Cell Therapy Is Complemented by Oncolytic Virotherapy with Fusogenic VSV-NDV in Combination Treatment of Murine Melanoma.
Cancers – Special Issue
Advances and Future Prospects in Oncolytic Virus Immunotherapy